ADAPTIVE BIOTECHNOLOGIES CORPORATION Selling and Marketing Expense
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Selling and Marketing Expense of $26.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION selling and marketing expense for the quarter ending 2026-06-30 was $26.41M, a 12.05% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION selling and marketing expense for the quarter ending 2026-03-31 was $26.35M, a 14.31% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION selling and marketing expense for the quarter ending 2025-12-31 was $24.48M, a 13.47% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION selling and marketing expense for the quarter ending 2025-09-30 was $23.47M, a 14.20% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION selling and marketing expense for fiscal 2025 was $94.57M, a 11.58% increase from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION selling and marketing expense for fiscal 2024 was $84.76M, a 4.31% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION selling and marketing expense for fiscal 2023 was $88.58M, a 7.35% decline from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION selling and marketing expense for fiscal 2022 was $95.60M, a 0.14% increase from fiscal 2021.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.41M 10-Q · filed 2026-08-04 | $52.76M 10-Q · filed 2026-08-04 | $77.24M derived: sum of 3 quarters · filed 2026-08-04 | $100.71M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $26.35M 10-Q · filed 2026-05-05 | $50.83M derived: sum of 2 quarters · filed 2026-05-05 | $74.30M derived: sum of 3 quarters · filed 2026-05-05 | $97.87M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $24.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $47.95M derived: sum of 2 quarters · filed 2026-02-26 | $71.52M derived: sum of 3 quarters · filed 2026-08-04 | $94.57M 10-K · filed 2026-02-26 |
| 2025-09-30 | $23.47M 10-Q · filed 2025-11-05 | $47.04M derived: sum of 2 quarters · filed 2026-08-04 | $70.09M 10-Q · filed 2025-11-05 | $91.67M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $23.57M 10-Q · filed 2026-08-04 | $46.62M 10-Q · filed 2026-08-04 | $68.19M derived: sum of 3 quarters · filed 2026-08-04 | $88.75M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $23.05M 10-Q · filed 2026-05-05 | $44.62M derived: sum of 2 quarters · filed 2026-05-05 | $65.17M derived: sum of 3 quarters · filed 2026-05-05 | $85.49M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $21.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $42.13M derived: sum of 2 quarters · filed 2026-02-26 | $62.44M derived: sum of 3 quarters · filed 2026-02-26 | $84.76M 10-K · filed 2026-02-26 |
| 2024-09-30 | $20.55M 10-Q · filed 2025-11-05 | $40.87M derived: sum of 2 quarters · filed 2025-11-05 | $63.18M 10-Q · filed 2025-11-05 | $85.09M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $20.31M 10-Q · filed 2025-08-05 | $42.63M 10-Q · filed 2025-08-05 | $64.54M derived: sum of 3 quarters · filed 2026-02-26 | $85.03M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $22.32M 10-Q · filed 2025-05-01 | $44.23M derived: sum of 2 quarters · filed 2026-02-26 | $64.72M derived: sum of 3 quarters · filed 2026-02-26 | $88.59M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $21.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $42.40M derived: sum of 2 quarters · filed 2026-02-26 | $66.27M derived: sum of 3 quarters · filed 2026-02-26 | $88.58M 10-K · filed 2026-02-26 |
| 2023-09-30 | $20.49M 10-Q · filed 2024-11-07 | $44.37M derived: sum of 2 quarters · filed 2024-11-07 | $66.67M 10-Q · filed 2024-11-07 | $90.39M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $23.87M 10-Q · filed 2024-08-01 | $46.18M 10-Q · filed 2024-08-01 | $69.90M derived: sum of 3 quarters · filed 2025-03-03 | $91.41M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $22.31M 10-Q · filed 2024-05-07 | $46.02M derived: sum of 2 quarters · filed 2025-03-03 | $67.54M derived: sum of 3 quarters · filed 2025-03-03 | $91.82M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $23.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $45.23M derived: sum of 2 quarters · filed 2025-03-03 | $69.51M derived: sum of 3 quarters · filed 2025-03-03 | $95.60M 10-K · filed 2025-03-03 |
| 2022-09-30 | $21.51M 10-Q · filed 2023-11-09 | $45.79M derived: sum of 2 quarters · filed 2023-11-09 | $71.89M 10-Q · filed 2023-11-09 | $98.58M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $24.28M 10-Q · filed 2023-08-02 | $50.37M 10-Q · filed 2023-08-02 | $77.07M derived: sum of 3 quarters · filed 2024-02-29 | $102.02M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $26.09M 10-Q · filed 2023-05-03 | $52.79M derived: sum of 2 quarters · filed 2024-02-29 | $77.74M derived: sum of 3 quarters · filed 2024-02-29 | $100.95M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $26.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $51.65M derived: sum of 2 quarters · filed 2024-02-29 | $74.86M derived: sum of 3 quarters · filed 2024-02-29 | $95.47M 10-K · filed 2024-02-29 |
| 2021-09-30 | $24.95M 10-Q · filed 2022-11-03 | $48.16M derived: sum of 2 quarters · filed 2022-11-03 | $68.77M 10-Q · filed 2022-11-03 | $87.31M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $23.22M 10-Q · filed 2022-08-03 | $43.82M 10-Q · filed 2022-08-03 | $62.37M derived: sum of 3 quarters · filed 2023-02-14 | $76.84M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $20.60M 10-Q · filed 2022-05-04 | $39.15M derived: sum of 2 quarters · filed 2023-02-14 | $53.62M derived: sum of 3 quarters · filed 2023-02-14 | $67.95M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $18.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $33.02M derived: sum of 2 quarters · filed 2023-02-14 | $47.35M derived: sum of 3 quarters · filed 2023-02-14 | $61.36M 10-K · filed 2023-02-14 |
| 2020-09-30 | $14.47M 10-Q · filed 2021-11-03 | $28.81M derived: sum of 2 quarters · filed 2021-11-03 | $42.81M 10-Q · filed 2021-11-03 | $55.45M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $14.33M 10-Q · filed 2021-08-04 | $28.34M 10-Q · filed 2021-08-04 | $40.98M derived: sum of 3 quarters · filed 2022-02-15 | $50.08M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $14.01M 10-Q · filed 2021-05-05 | $26.65M derived: sum of 2 quarters · filed 2022-02-15 | $35.75M derived: sum of 3 quarters · filed 2022-02-15 | $44.64M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $12.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $21.74M derived: sum of 2 quarters · filed 2022-02-15 | $30.64M derived: sum of 3 quarters · filed 2022-02-15 | $38.45M 10-K · filed 2022-02-15 |
| 2019-09-30 | $9.10M 10-Q · filed 2020-11-10 | $18.00M derived: sum of 2 quarters · filed 2020-11-10 | $25.81M 10-Q · filed 2020-11-10 | $33.88M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $8.90M 10-Q · filed 2020-08-10 | $16.71M 10-Q · filed 2020-08-10 | $24.79M derived: sum of 3 quarters · filed 2021-02-24 | $30.82M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $7.82M 10-Q · filed 2020-05-12 | $15.89M derived: sum of 2 quarters · filed 2021-02-24 | $21.93M derived: sum of 3 quarters · filed 2021-02-24 | $27.26M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $8.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $14.11M derived: sum of 2 quarters · filed 2021-02-24 | $19.44M derived: sum of 3 quarters · filed 2021-02-24 | $24.49M 10-K · filed 2021-02-24 |
| 2018-09-30 | $6.04M 10-Q · filed 2019-11-12 | $11.37M derived: sum of 2 quarters · filed 2019-11-12 | $16.41M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $5.33M 10-Q · filed 2019-08-13 | $10.38M 10-Q · filed 2019-08-13 | ||
| 2017-12-31 | $16.77M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |